Company Overview: Soleno Therapeutics (NASDAQ: SLNO) is a biotech company focused on rare diseases, best known for developing VYKAT™ XR (diazoxide choline). VYKAT XR is the first and only FDA-approved treatment for the hallmark hyperphagia (insatiable hunger) of Prader-Willi Syndrome (PWS) (neurocrine.gcs-web.com). After FDA approval in March 2025, Soleno successfully launched VYKAT XR in the U.S., achieving $190 million in 2025 revenue (with $92 million in Q4 alone) (neurocrine.gcs-web.com). This early commercial success quickly turned Soleno profitable, a rare feat for a small biotech – the company reported net income of ~$20.9 million in 2025 after years of losses (cdn.yahoofinance.com). Soleno’s stock reflected this trajectory, soaring from under $2 in early 2023 to almost $90 per share by mid-2025 (www.biopharmadive.com). However, momentum stalled in late 2025 amid safety concerns and a short-seller attack (see “Risks & Red Flags” below). In April 2026, larger pharma Neurocrine Biosciences agreed to acquire Soleno for $53.00 per share in cash ( ~$2.9 billion) (neurocrine.gcs-web.com) (m.investing.com). This buyout price is about a 34% premium to Soleno’s pre-announcement stock price (m.investing.com) and effectively caps SLNO’s value at the deal terms. Notably, a securities fraud class action was filed against Soleno in late 2025, alleging the company misled investors about VYKAT XR’s prospects. Shareholders who bought SLNO between March 26 and August 4, 2025 may be part of this class period (www.newsfilecorp.com), and the lead plaintiff filing deadline is May 5, 2026 (www.newsfilecorp.com) – an urgent consideration for investors. Below, we dive into Soleno’s fundamentals – dividend policy, leverage, coverage, valuation – and the key risks and open questions surrounding this story.
Dividend Policy & Yield
Soleno has never paid a dividend on its common stock, and it does not plan to pay dividends in the foreseeable future (cdn.yahoofinance.com) (cdn.yahoofinance.com). As a clinical-stage biopharmaceutical company, Soleno historically reinvested all capital into R&D and commercialization rather than returning cash to shareholders. Management explicitly states that any future dividends would depend on earnings, capital needs, and financial condition, but currently an “expected dividend yield of zero” is assumed (cdn.yahoofinance.com) (cdn.yahoofinance.com). In short, SLNO offers no dividend yield, and income-oriented metrics like FFO/AFFO do not apply to this biotech’s equity. Shareholder returns hinge entirely on stock price appreciation (or, in this case, the $53/share buyout offer) rather than income.
– Dividend history: No dividends ever declared or paid (cdn.yahoofinance.com). – Current yield: 0%. No cash distribution; reinvestment of earnings into growth (cdn.yahoofinance.com). – Policy: Management does not anticipate any near-term change in this policy (cdn.yahoofinance.com), especially as the pending acquisition means Soleno’s stock will likely cease trading in a few months.
Tap to reveal how to get exposure pre-IPO
Leverage and Debt Maturities
Despite launching a commercial product, Soleno maintained a light debt load, largely funding operations through equity raises and a flexible credit facility. In December 2024, Soleno entered a Loan and Security Agreement with Oxford Finance for up to $200 million in term loans (cdn.yahoofinance.com). An initial tranche was drawn in late 2024 (with the remainder available upon milestones): after FDA approval of VYKAT XR in Q1 2025, an additional $50 million tranche became available but was not utilized (cdn.yahoofinance.com). By year-end 2025, Soleno had only partially drawn this facility – roughly $50 million outstanding, based on interest expense figures (see below). In fact, Soleno was in a net cash position: it held $70.1M in cash and $436.0M in marketable securities at 12/31/2025 (cdn.yahoofinance.com), compared to ~$50M in debt, meaning substantial liquidity far exceeded its debt.
The Oxford term loan bears a floating interest rate of 1-month SOFR + 5.50% (~10–11% annual at 2025 rates) (cdn.yahoofinance.com). Crucially, Soleno achieved a performance milestone in 2025 that extended the loan’s “interest-only” period – no principal repayment required for 60 months – and set a total term of 72 months (cdn.yahoofinance.com). This implies maturity in late 2030, with amortization of principal only beginning in February 2030 (cdn.yahoofinance.com). Thus, no significant debt maturities or mandatory repayments occur until 2030, affording the company (and its acquirer) long-term financial flexibility. The loan is secured by substantially all of Soleno’s assets (including IP) (cdn.yahoofinance.com) and includes typical covenants. Notably, a minimum revenue covenant kicks in by Q2 2026 if more than $50M is drawn (cdn.yahoofinance.com), but as of Dec 2025 Soleno stayed under that threshold.
3 Reasons people are racing to this pre-IPO proxy
Leverage metrics: With ~$50M debt vs ~$450M equity (book value) at year-end, Soleno’s debt-to-equity was only ~0.11. On a net basis (debt minus cash/investments), it had no net debt but rather net cash of ~$386M. Total liabilities were $113.7M against total assets of $563.8M (cdn.yahoofinance.com) (mostly cash/securities), underscoring a strong balance sheet. This conservative leverage profile is partly thanks to a July 2025 equity offering: Soleno issued ~2.71 million shares at $85 each, raising ~$230 million in new capital (cdn.yahoofinance.com) when the stock was riding high. That equity raise, plus growing sales, allowed Soleno to avoid drawing more debt capital despite having access to it (cdn.yahoofinance.com) (cdn.yahoofinance.com).
– Debt outstanding: ~$50 million term loan (Oxford Finance) as of 2025 (interest-only, floating ~10%) (cdn.yahoofinance.com). No other long-term debt disclosed (aside from lease liabilities and minor warrant liabilities). – Maturities: Oxford loan matures ~Dec 2030 (72-month term) (cdn.yahoofinance.com). Principal payments start Feb 2030, giving 4+ years before any amortization (cdn.yahoofinance.com). – Liquidity: $506M in cash & investments vs $50M debt provides ample debt coverage and flexibility (cdn.yahoofinance.com). Even post-2025 launch investments, Soleno’s cash runway was strong, reducing any refinancing risk. – Covenants: No dividends, new liens, or major acquisitions without lender consent (cdn.yahoofinance.com). A revenue covenant would require meeting certain sales levels by mid-2026 if >$50M of the facility is used (cdn.yahoofinance.com) (not triggered as of 2025).
Coverage and Cash Flow
Interest coverage is robust given Soleno’s newly positive earnings and low interest burden. In 2025, Soleno incurred $5.5 million in interest expense on its debt (cdn.yahoofinance.com). This was a small fraction of revenue (about 2.9% of $190M sales) and was comfortably covered by operating profits. For the full year 2025, Soleno’s net income of $20.9M was roughly 4 times its interest expense (cdn.yahoofinance.com) (cdn.yahoofinance.com), implying that EBIT/interest coverage was in the same ballpark (even higher if adding back non-cash charges). Additionally, Soleno earned significant interest income on its large cash balance, which helped offset interest expense (cdn.yahoofinance.com). The net result was that “other income (expense)” was positive in 2025, meaning interest costs posed no drag on the bottom line (cdn.yahoofinance.com).
Cash flow coverage: Soleno generated $46.8 million of net cash from operating activities in 2025 (cdn.yahoofinance.com) thanks to VYKAT XR’s strong launch and an upfront payment from its sale of a Priority Review Voucher (PRV) earlier in the year (the PRV sale is noted in Soleno’s filings as a significant one-time cash inflow). This operating cash flow comfortably covered the $4.5M of cash interest paid in 2025 (cdn.yahoofinance.com). In fact, Soleno’s operations were cash-flow positive even after investing in the drug launch and pipeline R&D, a positive sign for coverage. With interest-only debt through 2029, annual interest costs (~$5M) should remain easily serviced by expected cash flows, especially once integrated into Neurocrine’s profitable platform (Neurocrine itself generates substantial cash, easing any future debt servicing). Overall, Soleno’s interest obligations are minimal relative to its earnings and cash, indicating low financial risk from leverage.
Dividend coverage: Not applicable, as Soleno pays no dividend. All cash flow is reinvested or, in the case of acquisition, will accrue to the acquirer’s benefit rather than being paid out.
Valuation
At the agreed acquisition price of $53.00 per share, Soleno’s equity is valued at approximately $2.9 billion (neurocrine.gcs-web.com). This represents a rich valuation relative to the company’s current financials, which is typical for a high-growth biotech with a unique drug:
– Price-to-Sales (P/S): ~15.3× based on $190M revenue in 2025 (neurocrine.gcs-web.com). In other words, Neurocrine is paying about 15 times Soleno’s last-year sales for the rights to VYKAT XR and its future growth. On an enterprise value basis (subtracting ~$456M net cash), the EV/Sales was around 12×. This multiple reflects the expectation of significant revenue growth in coming years as the PWS market is further penetrated (and possibly globalized). By comparison, established large biopharma companies often trade at lower single-digit sales multiples, but Soleno’s first-in-class drug and fast growth command a higher premium.
– Price-to-Earnings (P/E): ~130× trailing 2025 earnings. With ~$20.9M net income (cdn.yahoofinance.com), a $2.9B price tag implies a very high trailing P/E. However, this is somewhat misleading because 2025 was Soleno’s first profitable year and included heavy launch investments and some one-time items. Forward earnings are expected to ramp up dramatically as sales grow against a relatively fixed cost base. In fact, consensus forecasts before the buyout anticipated P/E dropping into the teens in 2026 and single-digits by 2027. Market data showed Soleno was projected at ~13× 2026 P/E and ~8× 2027 P/E at the $53 price (www.marketscreener.com), indicating analysts expected explosive earnings growth (VYKAT XR reaching broader patient uptake, improved margins, etc.). These forward multiples suggest the price, while steep on backward-looking metrics, could prove very reasonable if VYKAT’s trajectory meets bullish expectations.
– Price-to-Book (P/B): ~6.1×. Soleno’s stockholders’ equity was ~$450M at end of 2025, largely from recent capital raises and retained profit (cdn.yahoofinance.com). The $2.9B valuation is roughly six times that book value. A high P/B is common for pharma companies where the primary assets are intangible (drug IP and future pipeline) not fully reflected on the balance sheet. Neurocrine is valuing Soleno for the earning power of VYKAT XR and pipeline optionality, rather than its current book assets.
– Deal Premium: +34% vs. Soleno’s last closing price before takeover news (m.investing.com). It’s also about +51% above the 30-day average price (www.biopharmadive.com). This premium reflects both the strategic value of VYKAT XR and the fact that Soleno’s shares had slumped from their 2025 highs (partly due to short-seller pressure). For longer-term context, the $53 deal is well below the ~$85–90 peak in summer 2025 (www.biopharmadive.com), which some investors expected the company to eventually regain absent a buyout. Nevertheless, once the acquisition was announced, Wall Street broadly accepted $53 as the ceiling – multiple analysts immediately downgraded SLNO to “Hold/Neutral” and cut their price targets to $53 (from prior targets as high as $85–115) (www.marketscreener.com), essentially indicating no upside beyond the deal price. The stock now trades just under $53, reflecting the anticipated merger closure minus a small arbitrage discount.
In summary, Soleno’s valuation is driven by growth potential rather than current fundamentals. The deal values Soleno at a rich multiple of current earnings and sales, but that is underpinned by VYKAT XR’s promise in an unmet medical need. Neurocrine, by paying ~$2.9B, is wagering that VYKAT XR will become a durable, high-growth franchise (and perhaps exceed the controversies). Investors who bought Soleno earlier at much lower prices will realize substantial gains via the buyout, whereas those who bought near the peak have a more mixed outcome. Valuation now is effectively fixed by the agreed acquisition, barring any competing bids or deal failure, neither of which appears likely at this stage.
Risks, Red Flags & Open Questions
While Soleno achieved a remarkable turnaround with VYKAT XR, it also encountered serious controversies and risks that continue to shadow the story:
– Securities Class Action: Multiple shareholder rights law firms have filed suit alleging Soleno misled investors about the safety, efficacy, and commercial prospects of VYKAT XR (formerly called DCCR in trials) (www.hbsslaw.com). The complaint claims that Soleno’s management “systematically downplayed or concealed significant evidence of safety concerns” in the Phase 3 clinical program (www.hbsslaw.com). In particular, excess fluid retention and cardiac safety issues in some trial participants may have been underreported. The lawsuit cites that Soleno executives gave glowing assessments (e.g. launch going “really well” and exceeding expectations) while allegedly knowing about serious adverse events (www.hbsslaw.com) (www.hbsslaw.com). Investors were blindsided when these problems came to light, causing the stock to plunge. If these allegations hold merit, Soleno (or its successor, Neurocrine) could face legal liabilities or settlements. The deadline of May 5, 2026 for lead plaintiff motions is imminent (www.newsfilecorp.com) – interested shareholders need to act urgently. Open question: Will evidence show intentional misrepresentation by management, or just unforeseen issues? The outcome of this case may not derail the Neurocrine deal, but it could lead to financial penalties or admissions of wrongdoing down the line.
– Short-Seller Report & Safety Concerns: On August 15, 2025, activist short-seller Scorpion Capital released a scathing report on Soleno, raising multiple red flags (www.hbsslaw.com) (www.hbsslaw.com). Chief among them were safety issues with VYKAT XR: Scorpion pointed to a “rapid pile-up of reports of children hospitalized for potential heart failure” shortly after starting VYKAT (www.hbsslaw.com). The report alleged that VYKAT’s mechanism (an extended-release form of diazoxide) can cause severe edema and cardiovascular stress in some PWS patients, posing greater safety risks than Soleno had disclosed (www.hbsslaw.com). These allegations sparked significant concern – Soleno’s share price dropped ~40% between mid-August and early November 2025 (www.hbsslaw.com) as investors grappled with the news. Soleno’s management partially acknowledged the issue on its Q3 2025 earnings call (Nov 4, 2025), admitting “a disruption in our launch trajectory in the wake of [the] short seller report… in the form of a lower number of start forms and increased discontinuations for non-serious adverse events.” (www.hbsslaw.com) In other words, after Scorpion’s expose, fewer new patients began therapy and more existing patients stopped treatment (even if side effects were “non-serious” like fluid retention, it impacted compliance). This confirms that the safety scare hurt VYKAT’s uptake. The drug’s label presumably carries warnings (diazoxide is known to cause fluid retention), but the extent of real-world side effects is an ongoing risk. Open questions: Will further safety data (e.g. post-marketing studies) reveal more serious cardiac issues? Could regulators impose additional warnings or usage restrictions? Neurocrine will need to closely monitor and manage these risks; a severe safety event could not only harm patients but also derail the drug’s commercial potential.
– Reliance on a Single Prescriber & Data Integrity Concerns: Scorpion’s report also alleged that Soleno’s early sales were highly concentrated to a single physician in Florida who was a lead investigator in VYKAT’s trials (www.hbsslaw.com). It was implied this doctor’s enthusiastic prescribing “fueled” the initial launch metrics, raising questions about the breadth of demand. If true, once that physician’s patient backlog was exhausted or if he faced scrutiny, new prescriptions might slow sharply. Moreover, Scorpion scrutinized some clinical papers co-authored by that investigator, claiming they showed “irregularities… casting doubt on the validity of SLNO’s trials and FDA submissions.” (www.hbsslaw.com) This essentially questions the integrity of the clinical data underlying VYKAT’s approval. These are very serious allegations – if any data manipulation occurred, it could prompt regulatory investigations or at least tarnish the credibility of Soleno’s management and science. To be clear, no proof of fraud has been confirmed publicly; the FDA did approve VYKAT XR, suggesting the agency was satisfied with the trial data. However, the cloud of doubt remains a red flag. Neurocrine conducted due diligence before the acquisition, so it presumably gained comfort that the data is sound or the issues are not systemic. Still, investors will watch for any new revelations (from whistleblowers, the class action discovery, or Neurocrine’s own analyses) about the trial conduct. Open question: Did Soleno’s trial truly demonstrate VYKAT’s safety/efficacy, or will deeper examination uncover flaws? The answer will impact long-term trust in this product.
– Regulatory and Market Uncertainty (EU Withdrawal): Soleno had been seeking approval for VYKAT XR in Europe, but Europe’s regulators were not easily convinced. By early 2026, there was a pending EMA decision expected mid-year, yet it was “not seen as a sure thing” due to the questions around the drug (www.biopharmadive.com). In fact, on April 7, 2026 – just ahead of the Neurocrine deal announcement – Soleno withdrew its European marketing authorization application for VYKAT (www.marketscreener.com). This withdrawal likely indicates that Soleno sensed a negative outcome or major hurdles in Europe (potentially related to the safety profile or data questions). It could also be a strategic move to let Neurocrine re-file or address issues anew. Either way, absence of EU approval curtails near-term growth (the drug currently is only sold in the U.S.). Neurocrine will have to decide whether to pursue approval in Europe later, and if so, under what conditions. Open questions: Can VYKAT XR eventually secure approval outside the U.S., and how will differing regulatory standards (perhaps more cautious on safety) affect its global rollout? The success in Europe (or lack thereof) will influence the drug’s ultimate market potential and the acquisition’s payoff.
– Growth Trajectory Concerns: Even within the U.S., some analysts have become cautious about VYKAT’s long-term sales trajectory. The short-seller episode revealed that after an initial burst, patient demand might be leveling off more quickly than hoped. By Q4 2025, Soleno still showed strong revenue ($92M) (neurocrine.gcs-web.com), but it’s unclear if that pace is fully sustainable. The slowdown in “start forms” (new patient enrollments) in late 2025 suggests that many early adopter patients were already on drug, and growth must come from expanding to new prescribers and patients. Retention is another factor – if a notable percentage of patients discontinue due to side effects or inadequate benefit, net growth will suffer. BioPharma Dive notes that these trends “stoked questions among investors and analysts about the drug’s growth trajectory” (www.biopharmadive.com). Some on Wall Street describe VYKAT as a “controversial” drug and are uncertain “how confident” to be in its future uptake (www.biopharmadive.com). Another wrinkle: competition could emerge. While VYKAT is first-to-market, other companies may develop PWS treatments (for example, competitors might target the hormonal pathways or appetite centers differently). If a safer or more efficacious therapy comes along, Vykat could face pressure. Open questions: How large is the true addressable market for VYKAT (PWS patient share willing to go on chronic therapy)? Will growth re-accelerate with Neurocrine’s larger sales force, or has the easy part of the market been mostly captured in year one?* Soleno’s prior management was very optimistic, but now the baton passes to Neurocrine to prove the drug’s commercial durability.
– Acquisition Execution and Timeline: Neurocrine’s acquisition is expected to close by early Q3 2026 (within ~90 days of the April announcement), pending regulatory approvals and the tender of a majority of shares (neurocrine.gcs-web.com). There is little anticipated antitrust issue (Neurocrine has no competing product in PWS), and both boards have approved the deal (www.biopharmadive.com). While the probability of closure is high, one risk would be any material adverse change before closing – for instance, if an unexpected serious safety event or FDA action on VYKAT occurred, or if Soleno’s financials dramatically deteriorated. Such an event could give Neurocrine pause or an opportunity to renegotiate. Another risk, albeit seemingly low, is a higher bid from another party. No rival bidders have emerged so far, and given the drug’s contentious backdrop, it appears Neurocrine was the most willing buyer at a generous price.
Finally, from an investor standpoint, one open question is how the class action and any related findings might impact the post-merger company. If Soleno did engage in any misconduct, Neurocrine (as the new owner) might inherit reputational risks or financial liabilities. Neurocrine has stated the deal will be financed with cash on hand and a bit of new debt (www.biopharmadive.com) – they clearly believe VYKAT XR will more than pay for itself in the long run. Will that bet pay off? It hinges on resolving or managing the risks above.
In summary, Soleno Therapeutics offers a case study in high reward but high risk biotech investing. The company brought a novel rare-disease drug to market and achieved rapid profitability, attracting a multi-billion dollar takeover. Yet, serious red flags – safety concerns, allegations of misrepresentation, and uncertain long-term growth – surround the story. Shareholders must weigh these factors, especially those in the class period who have to decide whether to opt into the lawsuit by the fast-approaching deadline (www.newsfilecorp.com). Going forward, Neurocrine’s challenge will be to restore confidence in VYKAT XR’s safety profile, expand its usage responsibly, and perhaps address the questions left in Soleno’s wake. Investors will be watching how Neurocrine navigates these issues and whether VYKAT’s promise can overcome the controversies. The upside is significant if VYKAT XR becomes a standard-of-care therapy for PWS globally. The downside risks – from safety or legal blowbacks – are also non-negligible. As the class action slogan suggests, “Act Now!” is apt: it’s a pivotal moment for all parties involved in SLNO, with tomorrow’s deadline symbolic of the urgency to get to the truth and secure stakeholder rights.
___
Sources: Soleno 2025 10-K (SEC filings) (cdn.yahoofinance.com) (cdn.yahoofinance.com); Company press releases and investor materials (neurocrine.gcs-web.com) (neurocrine.gcs-web.com); Reuters and BioPharmaDive news reporting (m.investing.com) (www.biopharmadive.com); Hagens Berman case brief (class action details) (www.hbsslaw.com) (www.hbsslaw.com); Oxford Finance loan details (cdn.yahoofinance.com); Analyst commentary (MarketScreener) (www.marketscreener.com); and other cited references throughout.
For informational purposes only; not investment advice.